If The Subject Is A Male Of Child Fathering Potential, Does He Agree To Practice Adequate Birth Control While Receiving Treatment And For Six Months After Treatment Is Discontinued (If the subject is a male of child fathering potential, does he agree to practice adequate birth control while receiving treatment and for six months after treatment is discontinued)
CL Item
Date Informed Consent Obtained (Date informed consent obtained)
CL Item
Do The Subject's Granulocytes (anc) Measure >= 1000 Mm^3 And Platelets >= 75,000 Dl (unless These Parameters Are Abnormal Secondary To Lymphomatous Involvement Of Bone Marrow, Or Due To Hiv-related Thrombocytopenia) (Do the subject's granulocytes (ANC) measure >= 1000 mm^3 and platelets >= 75,000 dL (unless these parameters are abnormal secondary to lymphomatous involvement of bone marrow, or due to HIV-related thrombocytopenia))
CL Item
Does The Patient Have The Ability And Willingness To Give Informed Consent? (Does the patient have the ability and willingness to give informed consent?)
CL Item
Does The Subject Have Documented Hiv Infection (documentation May Be Serologic [elisa, Western Blot], Culture, Or Quantitative Pcr Or Bdna Assays. Prior Documentation Of Hiv Seropositivity Is Acceptable) (Does the subject have documented HIV infection (Documentation may be serologic [ELISA, western blot], culture, or quantitative PCR or bDNA assays. Prior documentation of HIV seropositivity is acceptable))
CL Item
Does The Subject Have Either Measurable Or Non-measurable Tumor Parameter(s) Non-measurable Tumor Parameters Are Defined As Not Having Bidimensional Measurements But Can Be Followed For Response By Other Diagnostic Tests (Does the subject have either measurable or non-measurable tumor parameter(s) Non-measurable tumor parameters are defined as not having bidimensional measurements but can be followed for response by other diagnostic tests)
CL Item
Does The Subject Have Previously Untreated, Histologically Or Cytologically Documented B-cell Non-hodgkin's Lymphoma (Does the subject have previously untreated, histologically or cytologically documented B-cell non-Hodgkin's lymphoma)
CL Item
Does The Subject's Bilirubin Measure <= 2.0 Mg/dl (unless Elevated Secondary To Lymphomatous Involvement Of Liver Or Biliary System, Or Due To Other Hiv Medications [e.g., Indinavir Or Atazanavir]) (Does the subject's bilirubin measure <= 2.0 mg/dL (unless elevated secondary to lymphomatous involvement of liver or biliary system, or due to other HIV medications [e.g., indinavir or atazanavir]))
CL Item
Does The Subject's Creatinine Measure <= 2.0 Mg/dl Or Is Creatinine Clearance >= 60 Ml/min (unless Secondary To Renal Involvement By Lymphoma) (Does the subject's creatinine measure <= 2.0 mg/dL or is creatinine clearance >= 60 mL/min (unless secondary to renal involvement by lymphoma))
CL Item
If The Subject Is Female Capable Of Childbearing, Does She Agree To Practice Adequate Birth Control To Prevent Pregnancy While Receiving Treatment And For Six Months After Treatment Is Discontinued (If the subject is female capable of childbearing, does she agree to practice adequate birth control to prevent pregnancy while receiving treatment and for six months after treatment is discontinued)
CL Item
If The Subject Is Female, Has She Had A Negative Pregnancy Test Within 72 Hours Prior To Study Entry (If the subject is female, has she had a negative pregnancy test within 72 hours prior to study entry)
CL Item
Is The Disease One Of The Following Histologies: Follicular Large-cell (grade 3), Dlbcl, Immunoblastic, Plasmablastic, Or Primary Effusion Lymphoma (Is the disease one of the following histologies: follicular large-cell (Grade 3), DLBCL, immunoblastic, plasmablastic, or primary effusion lymphoma)
CL Item
Is The Subject Receiving Concurrent Effective Haart (with Any Licensed Agents, Or Any Agent Available On An Expanded Access Program) (Is the subject receiving concurrent effective HAART (with any licensed agents, or any agent available on an expanded access program))
CL Item
Is The Subject's Left Ventricular Ejection Fraction (lvef) At Or Above The Lower Institutional Limits Of Normal, As Assessed By Muga Scan Or Echocardiogram, Obtained Within The 6 Weeks Prior To Registration (Is the subject's left ventricular ejection fraction (LVEF) at or above the lower institutional limits of normal, as assessed by MUGA scan or echocardiogram, obtained within the 6 weeks prior to registration)
CL Item
Is The Subject's Lymphoma Cd20-positive (Is the subject's lymphoma CD20-positive)
CL Item
Patient's Age (in Years) (Patient's age (in years))
CL Item
Karnofsky Performance Status (must Be > 50%) (Karnofsky Performance Status (must be > 50%))
Is The Subject Already Receiving Erythropoietin Or G-csf For Treatment Of Hiv-related Cytopenia If Yes, Will Growth Factors Be Discontinued At Least 24 Hours Prior To Chemotherapy (Is the subject already receiving erythropoietin or G-CSF for treatment of HIV-related cytopenia If yes, will growth factors be discontinued at least 24 hours prior to chemotherapy)
CL Item
Does The Subject Have A History Of Cytotoxic Chemotherapy Or Radiotherapy For This Lymphoma (Does the subject have a history of cytotoxic chemotherapy or radiotherapy for this lymphoma)
CL Item
Does The Subject Have A Second Active Tumor, Other Than Non-melanomatous Skin Cancer, Carcinoma In Situ Of The Cervix Or Kaposi's Sarcoma That Does Not Require Systemic Therapy (Does the subject have a second active tumor, other than non-melanomatous skin cancer, carcinoma in situ of the cervix or Kaposi's sarcoma that does not require systemic therapy)
CL Item
Does The Subject Have A Serious, Ongoing, Non-malignant Disease Or Infection, Which, In The Opinion Of The Investigator And/or Sponsor, Would Compromise Protocol Objectives (Does the subject have a serious, ongoing, non-malignant disease or infection, which, in the opinion of the Investigator and/or Sponsor, would compromise protocol objectives)
CL Item
Does The Subject Have An Acute, Intercurrent Infection (excluding Mycobacterium Avium) That May Interfere With Planned Protocol Treatment (Does the subject have an acute, intercurrent infection (excluding Mycobacterium avium) that may interfere with planned protocol treatment)
CL Item
Does The Subject Have History Of Cutaneous Or Mucocutaneous Reactions Or Diseases, Due To Any Cause, Severe Enough To Cause Hospitalization Or An Inability To Eat Or Drink For >= 2 Days (Does the subject have history of cutaneous or mucocutaneous reactions or diseases, due to any cause, severe enough to cause hospitalization or an inability to eat or drink for >= 2 days)
CL Item
Does The Subject Have Inadequate Pulmonary Function (i.e., Shortness Of Breath At Rest, With Arterial Po\2 < 70 Or Pulse Oximeter-derived O\2 Saturation < 94% On Room Air [unless Due To Lymphomatous Involvement Of The Lungs]) (Does the subject have inadequate pulmonary function (i.e., shortness of breath at rest, with arterial PO\2 < 70 or pulse oximeter-derived O\2 saturation < 94% on room air [unless due to lymphomatous involvement of the lungs]))
CL Item
Does The Subject Have Leptomeningeal Disease (positive Csf For Lymphoma) Or A Presence Of Metastatic Disease Of The Brain In Terms Of Any Mass Lesion (Does the subject have leptomeningeal disease (positive CSF for lymphoma) or a presence of metastatic disease of the brain in terms of any mass lesion)
CL Item
Does The Subject Have Primary Cns Lymphoma (this Includes Parenchymal Brain Or Spinal Chord Lymphoma) (Does the subject have primary CNS lymphoma (this includes parenchymal brain or spinal chord lymphoma))
CL Item
Has The Subject Had A Myocardial Infarction (mi) Within The 6 Months Prior To Study Entry, New York Heart Association (nyha) Class Ii Or Greater Heart Failure, Uncontrolled Angina, Severe Uncontrolled Ventricular Arrhythmias, Clinically Significant (Has the subject had a myocardial infarction (MI) within the 6 months prior to study entry, New York Heart Association (NYHA) Class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant)
CL Item
Has The Subject Had Any Major Surgery (excluding Diagnostic Surgery) Within The 4 Weeks Prior To Study Entry (Has the subject had any major surgery (excluding diagnostic surgery) within the 4 weeks prior to study entry)
CL Item
Has The Subject Received Rituximab Therapy Within The 12 Months Prior To Study Entry (Has the subject received rituximab therapy within the 12 months prior to study entry)
CL Item
If The Patient Is A Female, Is She Pregnant Or Nursing? (If the patient is a female, is she pregnant or nursing?)
CL Item
In The Opinion Of The Principal Investigator, Is The Subject Unable To Comply With The Requirements Of The Protocol, Or Unable To Provide Adequate Informed Consent (In the opinion of the Principal Investigator, is the subject unable to comply with the requirements of the protocol, or unable to provide adequate informed consent)
CL Item
Is The Subject Receiving Zidovudine As Part Of The Harrt Regimen (Is the subject receiving zidovudine as part of the HARRT regimen)
CL Item
Is The Subject's Expected Survival < 2 Months (Is the subject's expected survival < 2 months)